Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tickborne Diseases of the United States








Ehrlichiosis						Print
											PAGE 8 of 18
					**‹**View Table of Contents					Related Pages
										Agents*Ehrlichia chaffeensis, Ehrlichia ewingii, Ehrlichia muris eauclairensis*Ehrlichiosis can be severe or, in rare cases, fatal.
Incidence of *E. chaffeensis* enhrlichiosis generally increases with age, however, case-fatality rates are highest among children aged <10 years and adults aged ≥70 years.Ehrlichiosis blood smearWhere FoundEhrlichiosis is most frequently reported from the southeastern and south-central United States, from the East Coast extending westward to Texas. The areas from which most cases are reported correspond with the known geographic distribution of the lone star tick (*Amblyomma americanum*), which is associated with transmission of both *E. chaffeensis* and *E. ewingii*. In 2019, four states (Missouri, Arkansas, North Carolina, and New York) accounted for nearly half of all reported cases of *E. chaffeensis* ehrlichiosis. Since 2009, >115 cases of ehrlichiosis caused by *E. muris eauclairensis* have been identified in patients in the Upper Midwest. The tick responsible for transmitting this new subspecies of *Ehrlichia* is *Ixodes scapularis*, and the clinical presentation is generally similar to those associated with infections caused by *E. chaffeensis* and *E. ewingii*.Incubation Period5–14 daysSigns and SymptomsFever, chills
Headache
Malaise
Muscle pain
Gastrointestinal symptoms (nausea, vomiting, diarrhea, anorexia)
Altered mental status
Rash (more commonly reported among children)The Signs and Symptoms list presents symptoms commonly seen with ehrlichiosis. However, it is important to note that few people will develop all symptoms, and the number and combination of symptoms varies greatly from person to person.Warning symbol
**CONFIRMATION OF THE DIAGNOSIS IS BASED ON LABORATORY TESTING, BUT ANTIBIOTIC THERAPY SHOULD NOT BE DELAYED IN A PATIENT WITH A SUGGESTIVE CLINICAL PRESENTATION.**General Laboratory FindingsTypically observed during the first week of clinical disease:
Thrombocytopenia
Leukopenia (absolute)
Anemia (generally occurs later in illness than thrombocytopenia or leukopenia)
Mild to moderate elevations in hepatic transaminasesDuring the acute stage of illness, morulae can be detected in about 20% of patients. *E. chaffeensis* most commonly infects monocytes, whereas *E. ewingii* more commonly infects granulocytes. The target cell of *E. muris eauclairensis* has not yet been identified. Visualization of morulae during examination of blood smears is highly suggestive of a diagnosis; however, blood smear examination is insensitive and should never be relied upon solely to rule ehrlichiosis in or out.Laboratory DiagnosisDetection of DNA by PCR of whole blood. This method is most sensitive during the first week of illness and sensitivity can decrease after administration of tetracycline-class antibiotics.
Demonstration of a four-fold rise in IgG-specific antibody titer by indirect immunofluorescence antibody (IFA) assay in paired serum samples. The first sample should be taken within the first 2 weeks of illness, and the second should be taken 2 to 4 weeks later.
Immunohistochemical (IHC) staining of organism from skin, tissue, or bone marrow biopsies.**NOTE:** Antibody titers are frequently negative in the first 7–10 days of illness. Acute antibody results cannot independently be relied upon for confirmation.
**NOTE:** IgM antibodies are less specific than IgG antibodies and are more likely to generate false positives. IgM results alone should not be used for laboratory diagnosis.TreatmentAnaplasmosis, ehrlichiosis, and spotted fever group rickettsioses are treated with doxycycline. Clinical suspicion of any of these diseases is sufficient to begin treatment. **Delay in treatment may result in severe illness and death**. These regimens may need to be adjusted depending on a person’s age, medical history, underlying health conditions, pregnancy status, or allergies. Consult an infectious disease specialist in cases of pregnancy or life-threatening allergy to doxycycline.
Ehrlichiosis treatment regimen
Age Category
Drug
Dosage
Maximum
Duration (Days)**Adults**
Doxycycline
100 mg twice per day, orally or IV
100 mg/dose
Patients should be treated for at least 3 days after the fever subsides and until there is evidence of clinical improvement. Minimum course of treatment is 5-7 days.**Children weighing <100 lbs. (45.4 kg)**
Doxycycline
2.2 mg/kg per dose twice per day, orally or IV
100 mg/dose**NOTE:** Use doxycycline as first-line treatment for suspected ehrlichiosis in patients of all ages. The use of doxycycline to treat suspected ehrlichiosis in children is recommended by both the CDC and the American Academy of Pediatrics Committee on Infectious Diseases. Use of antibiotics other than doxycycline increases the risk of patient death. At the recommended dose and duration needed to treat ehrlichiosis, no evidence has been shown to cause staining of permanent teeth, even when multiple courses are given before the age of eight.ReferencesCenters for Disease Control and Prevention. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis—United States: a practical guide for health care and public health professionals. *MMWR* 2016; 65 (No.RR-2).
Dumler JS, Madigan JE, Pusterla N, et al. Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment. *Clin Infect Dis* 2007 Jul 15;45 Suppl 1:S45–51.
Engel J, Bradley K, et al. Revision of the national surveillance case definition for ehrlichiosis. Council of State and Territorial Epidemiologists, Infectious Diseases Committee, 2007 Position Statement [PDF – 7 pages].
Gelfand JA, Vannier E. *Ehrlichia chaffeensis* (human monocytotropic ehrlichiosis), *Anaplasma phagocytophilum* (human granulocytotropic anaplasmosis) and other ehrlichiae. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s *Principles and Practice of Infectious Diseases*. 6th ed. Philadelphia, PA: Churchill Livingstone; 2005. p. 2310–2318.
Harris, RM, Couturier BA, Sample SC. Expanded Geographic Distribution and Clinical Characteristics of *Ehrlichia ewingii* Infections, United States. *Emerg Infect Dis* 2016 May;22(5):862-865.
Johnson DK, Schiffman EK, Davis JP, et al. Human infection with *Ehrlichia muris*-like pathogen, United States, 2007-2013(1). *Emerg Infect Dis* 2015 Oct;21(10):1794-1799.
Mowla SJ, Drexler NA, Cherry CC, et al. Ehrlichiosis and anaplasmosis among transfusion and transplant recipients in the United States. *Emerg Infect Dis*. 2021 Nov;27(11):2768-2775.
Pritt BS, Sloan LM, Johnson DK, et al. Emergence of a new pathogenic *Ehrlichia* species, Wisconsin and Minnesota, 2009. *N Engl J Med* 2011; 365:422-429
Saha A, Browning C, Dandamudi R, et al. Donor-derived ehrlichiosis: 2 clusters following solid organ transplantation. *Clin Infect Dis*. 2022 Mar 9;74(5):918-923.
Todd SR, Dahlgren FS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain spotted fever. *J Pediatr* 2015 May;166(5):1246-1251.Top of Page

									Contents
			HomeTick IDOverview of Tickborne DiseasesLyme DiseaseTickborne Relapsing Fever (TBRF)Hard Tick Relapsing FeverAnaplasmosis**›****Ehrlichiosis**Rocky Mountain Spotted FeverRickettsia parkeri RickettsiosisTularemiaBabesiosisHeartland and Bourbon Virus DiseasesColorado Tick FeverPowassan Virus DiseaseTickborne Diseases AbroadTick Bites/PreventionLyme Disease Prophylaxis After Tick Bite
							
					
							Last Reviewed:  December 15, 2023						Source: 	Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases (DVBD)
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTickborne Diseases of the United StatesTick IDOverview of Tickborne DiseasesLyme DiseaseTickborne Relapsing Fever (TBRF)Hard Tick Relapsing FeverAnaplasmosisEhrlichiosisRocky Mountain Spotted Fever*Rickettsia parkeri*RickettsiosisTularemiaBabesiosisHeartland and Bourbon Virus DiseasesColorado Tick FeverPowassan Virus DiseaseTickborne Diseases AbroadTick Bites/PreventionLyme Disease Prophylaxis After Tick Bite


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue